Our Members

Associate Professor John Anthony Eden

Level 12
97-99 Bathurst St
Sydney, NSW 2000

1300 722 206

Directions

School of Women's and Children's Health
Royal Hospital for Women
Barker St
Randwick, NSW 2031

1300 722 206

Directions

Blue Shield Specialist Medical Centre
Level 3, 19 Kensington Street
Kogarah, NSW 2217

02 9382 6111

Directions

Special interests

  • Polycystic Ovarian Syndrome
  • Breast Cancer
  • Menopause

Medical Training

Qualifications

  • MB BS (Honours)
    University of NSW, 1979
  • MD
    University of NSW, 1989
  • MRCOG
    Royal College of Obstetricians & Gynaecologists, 1985
  • MRACOG
    Royal Australian College of Obstetricians & Gynaecologists, 1985.
  • FRCOG
    Royal College of Obstetricians & Gynaecologists, 1999
  • FRANZCOG
    Royal Australian & New Zealand College of Obstetricians & Gynaecologists, 1988.
  • CREI
    Certificate of Reproductive Endocrinology & Infertility (RACOG), 1991.

I have also passed the Part 1 examination of the Diploma of Diagnostic Ultrasound.

Outline of medical training

  • 7 January 1980 to 11 January 1981: Intern, St George Hospital Kogarah.
  • 12 January 1981 to 9 January 1983: Resident Medical Officer, St George Hospital.
  • 10 January 1983 to 13 January 1985: Registrar in Obstetrics & Gynaecology, St George Hospital.
  • 14 January 1985 to 12 January 1986: Senior Registrar in Obstetrics & Gynaecology, St George Hospital.

During the years I trained at St George Hospital, Kogarah, NSW, I was seconded to peripheral hospitals at Canterbury and Bankstown. I then accepted a position at Charing Cross Hospital London:

  • 1 May 1986 to 30 April 1988: Overseas Fellow in Obstetrics & Gynaecology, Charing Cross Hospital, London.
  • 1 May 1988 to 30 April 1989: Clinical Research Fellow in Gynaecological Endocrinology, Charing Cross Hospital.

The clinical research year was supported by a grant from the Trustee's Fellowship, Charing Cross Hospital. During these 3 years at Charing Cross Hospital, I worked in the Infertility Clinic, Ultrasound and Biochemistry Departments as a Clinical Research Fellow, spending about 1/3 of my time in clinical practice and the rest in research. I was involved in 2 clinical sessions per week, ran the ovulation induction service, had my own operating list and my own ultrasound session each week. I had a morning day-only list, which mostly consisted of laparoscopies, and an afternoon major surgery list for (mostly) tubal surgery.

Mr Michael Pawson was the consultant in charge and Dr Jamie Alaghband-Zadeh was Head of the Endocrine laboratory. I also worked with Dr Peter Wise, in the Endocrine department. I spent some time at the Lister Hospital learning in-vitro fertilization techniques.

I have considerable experience in using a variety of ovulation induction regimes, including using gonadotrophins, GnRH pump therapy and GnRH superagonists. I have been trained in colposcopy, use of the operating microscope and the microsurgical approach to tubal surgery. The ethics of infertility treatments, especially some of the newer (in vitro) treatments, is of particular interest. I am also very interested in counselling patients with fertility problems.

During my stay in the UK I worked closely with the IVF unit at the Cromwell Hospital and then the Lister Hospital, London. I worked with Mr John Studd and Mr Sam Abdullah. This has involved co-treatment of patients, research projects and the development of new hyperstimulation regimes using only ultrasound to monitor therapy. I am familiar with the procedural aspects of IVF.

I was awarded an MD from the University of NSW on 10 October 1989 for my thesis "A study of the hormonal factors influencing normal and abnormal ovarian follicular function with an emphasis on Insulin-like Growth Factor-1 (IGF1)". This was a study of human follicular fluid and also the polycystic ovary syndrome. Most of my thesis has been published in first-class journals and presented at international meetings. My thesis was supervised by Professor Steven Jeffcoate (Head, World Health Organization Standards Laboratory). Much of my work was also reviewed by Professor Howard Jacobs (Professor Reproductive Endocrinology, The Middlesex Hospital, London).

In 1991, I became certificated in reproductive endocrinology (RANZCOG), by passing the inaugural RANZCOG exam in this subspecialty. Since my return from the United Kingdom I have worked as a reproductive endocrinologist at the Royal Hospital for Women, Sydney and the St George Hospital, Kogarah (until 2000).

Senior Posts

  • Consultant Gynaecological Endocrinologist, St George Hospital, Kogarah. NSW. 1990- 2000
  • Senior Lecturer in reproductive endocrinology, UNSW, 1989-1996.
  • Associate-Professor in Reproductive Endocrinology (Fractional appointment), University of NSW, Royal Hospital for Women, Randwick, NSW. 1996-2015
  • Director, Sydney Menopause Centre, Royal Hospital for Women, Randwick, 1998-
  • Director, Barbara Gross Research Unit and Natural Therapy Unit, Royal Hospital for Women, Randwick, 1998-
  • Acting Medical Co-Director of Gynaecology, Royal Hospital from Women, October 2010 to July 2011
  • Medical Co-Director of Gynaecology, Royal Hospital from Women, 9.8.2011 – 14
  • Gynaecologist, Moree Aboriginal Health Service (Pius X) May 2009-
  • Visiting Medical officer, Royal Hospital for Women, 2015-
  • Conjoint Associate Professor UNSW 2015 -
  • Director Women’s Health and Research Institute of Australia, 2006-

Awards and Prizes

  1. Trustee's Fellowship, Charing Cross Hospital, London (1 May 1988 to 30 April 1989).
  2. Fotheringham Fellowship from the Royal Australian College of Obstetricians and Gynaecologists (1 January 1988 to 31 December 1989) to support my research into the control of ovarian follicular function.
  3. The President's prize, Royal Society of Medicine, Biochemistry section (7 February 1989) for research into ovarian growth factors.
  4. Watson Memorial Lecturer, St George Hospital Reunion Week, November 1990.
  5. Upjohn Prize for best scientific communication at the Australian Menopause Society Congress ("The effect of ageing on human follicular function"), Melbourne, 7 April 1992.
  6. Royal Australian College of Obstetricians and Gynaecologists Prize for best oral free communication, RACOG Scientific Meeting, Melbourne, 9 April 1992.
  7. North American Menopause Society prize for the best free communication, North American Menopause Society Meeting, San Diego, 2-4 September 1993.
  8. Best presentation by a recent graduate, Fertility Society of Australia, Brisbane meeting, 8-11 October 1994.
  9. The CIBA Menopause award (Australian Menopause Society) for "the most meritorious contribution to the field of menopausal medicine published by an Australian investigator"; May 1995.
  10. The Barbara Gross Prize (Australasian Menopause Society), for “best free communication”, October 26, 2001.
  11. Watson Memorial Lecturer, St George Hospital Reunion Week, September 2010
  12. Australasian Menopause Society for the best publication in the field of menopause for 2010

Research Money Raised

Peer-review grants

  • Title: "The role of IGF1 in the regulation of ovarian function"
    Year: 1988
    Source: The Trustee's Fellowship, Charing Cross Hospital, London.
    Amount: $31,583
    Progress: Completed
  • Title: Pathophysiology of the polycystic ovary syndrome and paracrine factors involved in the regulation of ovarian function.
    Year: 1988-9
    Source: The Fotheringham Fellowship, the Royal Australian College of Obstetricians and Gynaecologists.
    Amount: $30,000
    Progress: Completed
  • Title: The prevalence of polycystic ovaries amongst twins
    Year: 1992
    Source: NH&MRC
    Amount: Recommended, but not funded
    Progress: Completed
  • Title: The effects of hormone replacement therapy on cardiovascular reactivity in diabetic women
    Year: 1995-6
    Source: National Heart Foundation
    Amount: $99,230
    Co-investigators: Professor L Howes, Dr T Diamond
    Progress: Completed
  • Title: The effects of male and female sex hormones on endothelium-dependent dilatation in humans
    Year: 1996-7
    Source: National Heart Foundation
    Amount: $70,000
    Co-investigators: Dr David Celermajer, Professor Handelsman.
    Progress: Completed
  • Title: Quality of Life after Breast Cancer
    Years: 1997
    Source: Katherine Cunningham Foundation
    Amount: $30,000
    Co-investigators: Dr Wren, Kathy McFarlane, Dr Gross
    Progress: Completed
  • Title: A multicultural study of menopause
    Year: 2002-2003
    Source: Australasia Menopause Society
    Amount: $60,000
    Co-investigators: nil
    Progress: Completed
  • Title: A randomised controlled trial of herbals and supplements for PMT
    Year: 2007-
    Source: NH&MRC
    Amount:
    Co-investigators: Prof S Myers
    Progress: submitted (not successful)
  • Title: The use of complementary and alternative medicines among four ethnic groups of menopausal women living in Sydney: Implications for healthcare policy
    Year: 2010-2012
    Amount: $298,549
    Source: ARC Linkage Grant
    Progress: submitted (not successful)
  • Title: Sigma benchtop micro centrifuge, Fujitsu scanner
    Year: 2010
    Amount: $6,153.00
    Source: UNSW / Major equipment & infrastructure scheme.
    Progress: successful
  • Pilot Study of the Effects of Testosterone and Oestradiol Therapy Compared to Placebo on Clinical Indicators and Biomarkers of Dry Eye in Post?Menopausal Women
    Sponsor: Faculty of Science Interdisciplinary Research Grant UNSW
    Estimated income $5,000 (+$20,000 after publication)
    Status of study: Recruiting

Non-Peer Review Monies / Industry Funded Projects

  • Title: Double blind randomized trial of combined continuous Ogen 1.25mg and Provera (2.5/5/10mg).
    Years: 1990-4
    Source: Upjohn Pty Ltd
    Amount: $800,000
    Co-investigators: Dr Wren, Dr Webster
    Progress: Completed
  • Title: Double blind randomized trial of combined continuous Ogen 1.25mg and Provera (2.5/5/10mg).
    Years: 1997
    Source: Upjohn Pty Ltd
    Amount: $43,000
    Co-investigators: International group
    Progress: Completed
  • Title: Double blind randomized trial of combined continuous Premarin 0.625mg and Provera (2.5 or 5mg).
    Years: 1993-6
    Source: Wyeth-Ayerst
    Amount: $47,000
    Co-investigators: Multicentre international collaboration.
    Progress: Completed
  • Title: A study of combined continuous hormone replacement therapy amongst women with breast cancer.
    Year: 1994
    Source: Wyeth-Ayerst
    Amount: $40,000
    Co-investigators: Dr Wren, Dr Dew
    Progress: Completed
  • Title: Phytoestrogens as a potential treatment for menopausal symptoms, and to prevent osteoporosis, heart disease and cancer.
    Year: 1995-7
    Source: Sanitarium Pty Ltd
    Amount: $600,000
    Co-investigators: Dr Phillipa Wall.
    Progress: Completed
  • Title: A randomized, placebo controlled study of continuous combined low dose oestradiol-norethisterone patches for mild to moderate menopausal symptoms
    Year: 1995-6
    Source: Ciba-Geigy Pty Ltd
    Amount: $50,000
    Co-investigators: Multicentre international collaboration.
    Progress: Completed
  • Title: A randomized, controlled study of the effect of Oestradiol patches alone and Oestradiol patches and oral Provera on vascular reactivity
    Year: 1996-7
    Source: Upjohn & Ciba Geigy Pty Ltd
    Amount: $60,000
    Co-investigators: Dr Wren, Gross, Celermeyer, Kelly.
    Progress: Completed
  • Title: The effect of isoflavones on menopausal pathophysiology
    Year: 1995-8
    Source: Novogen Ltd
    Amount: $220,000
    Co-investigators: Mrs Jan Howes
    Progress: Completed
  • Title: The Barry Wren Scholarship
    Year: 1998-2004
    Source: Multiple donors
    Amount: $435,000
    Function: To fund research and educational projects in gynaecological endocrinology
  • Title: A randomized trial of PO-8 for menopausal symptoms
    Year: 1998
    Source: Novogen
    Amount: $100,000
    Co-investigators: Nil
    Progress: Completed
  • Title: A randomized trial of ginger for nausea
    Year: 1998-99
    Source: Eurovita P/L
    Amount: $70,000
    Co-investigators: Nil
    Progress: Completed
  • Title: A randomized trial of serenoa for benign prostatic hypertrophy
    Year: 1999-2000
    Source: Blackmore’s P/L
    Amount: $100,000
    Co-investigators: None
    Progress: Completed
  • Title: Progestesterone cream and the endometrium
    Year: 1998
    Source: Lawley Pharmaceuticals
    Amount: $35,000
    Co-investigators: None
    Progress: Completed
  • Title: A randomized trial of progesterone cream for menopause symptoms
    Year: 1999-2000
    Source: Lawley Pharmaceuticals
    Amount: $100,000
    Co-investigators: None
    Progress: Completed
  • Title: An international randomized trial of fosamax 35mg weekly versus 5mg daily for osteoporosis
    Year: 1998-2002
    Source: Merck Sharp Dohme Pharmaceuticals
    Amount: $59,000
    Co-investigators: International group
    Progress: Completed
  • Title: A randomized trial of Evista for osteoporosis
    Year: 2000-2007
    Source: Eli Lily
    Amount: $46,800
    Co-investigators: International group
    Progress: Commenced
  • Title: A randomized trial of Meno-eze for menopause symptoms
    Year: 2000-2001
    Source: Naturopathica
    Amount: $36,000
    Co-investigators: Nil
    Progress: Completed
  • Title: Dry eye study
    Year: 2000
    Source: in house
    Co-investigators: Uni of NSW Optometry School
    Progress: Completed
  • Title: Pharmacokinetic study of 2 hormonal creams
    Year: 2000
    Source: Lawley Pharmaceuticals
    Amount: $20,000
    Co-investigators: Professor L Howes
    Progress: Completed
  • Title: Meditation for severe migraines/menopausal flushing
    Year: 2000-5
    Source: in house
    Co-investigators: Dr Ramesh Manocha
    Progress: Completed
  • Title: A Multinational, multicentre, randomised, double-blind, parallel group, placebo controlled clinical trial of the effects of tibilone 1.25mg on the incidence of new fractures in osteoporotic postmenopausal women (LIFT).
    Year: 2001-2007
    Source: Organon
    Amount: $1,203,883
    Co-investigators: International group
    Progress: completed
  • Title: A double-blind randomised trial of 1% testosterone cream for female libido.
    Year: 2001-2002
    Source: Lawley Pharmaceuticals
    Amount: $90,000
    Co-investigators: International group
    Progress: Completed
  • Title: A Multinational, multicentre, randomised, double-blind, parallel group, placebo controlled clinical trial of the effects of Lasofoxifene (two doses) on the incidence of new fractures in osteoporotic postmenopausal women.
    Year: 2001-2007
    Source: Pfizer
    Amount: $171,000
    Co-investigators: International group
    Progress: completed
  • Title: A randomised controlled trial of an herbal tablet for tension headache
    Year: 2002-2003
    Source: Mediherb Australia
    Amount: $50,000
    Co-investigators: Nil
    Progress: Completed
  • Title: A randomised controlled trial of a herbal tablet cholesterol lowering
    Year: 2002-2003
    Source: Mediherb
    Amount: $50,000
    Co-investigators: Nil
    Progress: Completed
  • Title: A phase III, multinational, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of transdermal Testosterone (300 μg/day) for 24 weeks and safety for a further 28-week open-labelled period in women with Hypoactive Sexual Desire Disorder on concurrent estrogen replacement therapy who have undergone hysterectomy and bilateral oophorectomy.
    Year: 2001- 2007
    Amount: $23,422
    Source: Procter & Gamble
    Co-investigators: International group
    Progress: Completed
  • Title: A phase III, multination, randomised, double-blind, parallel-group, placebo-controlled 24-week study to evaluate the efficacy and safety of transdermal testosterone (300 μg/day) in naturally menopausal women with Hypoactive Sexual Desire Disorder on concurrent oral hormone replacement therapy.
    Year: 2001-2003
    Amount: $40,000
    Source: Procter & Gamble
    Co-investigators: International group
    Progress: Completed
  • Title: Multicultural context of menopause
    Year: 2002-2006
    Amount: $90,000
    Source: Australasian Menopause Society
    Co-investigators: nil
    Progress: Completed
  • Title: A randomised, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis (FACTS)
    Year: 2003 – 06
    Amount: $72,000
    Source: Merck Sharp & Dohme
    Co-Investigators: International group
    Progress: completed
  • Title: A multinational, multicenter, randomised, double-blind, parallel-group, placebo controlled clinical trial to investigate safety and efficacy of tibolone in women with climacteric symptoms and a history of breast cancer (LIBERATE)
    Year: 2003-2007
    Amount: $127,204
    Source: Organon P/L
    Co-investigators: International group
    Progress: Completed
  • Title: A phase III study of the efficacy and safety of Lasofoxifene in the treatment of vaginal atrophy in postmenopausal women.
    Year: 2003-2004
    Amount: $30,000
    Source: Pfizer
    Co-investigators: International group
    Progress: Completed
  • Title: A multicenter, randomised, double-blind, double dummy, group comparative trial to compare the effects of tibolone and transdermal continuous combined estradiol/norethisterone on the vaginal bleeding pattern, sexual desire and arousal in postmenopausal women with sexual dysfunction.
    Year: 2004-2005
    Amount: $20,500
    Source: Organon NV
    Co-investigators: International group
    Progress: Completed
  • Title: A multicenter, randomised, parallel group, double-blind, placebo controlled clinical trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomotor symptoms associated with the menopause.
    Year: 2004-07
    Amount: $88,671
    Source: Organon Australia
    Co-Investigators: International group
    Progress: completed
  • Title: Study assessing the effects on the endometrium and breast of a standardised isoflavone extracts (PHYTOSOYA) in post menopausal women.
    Year: 2005-07
    Amount: $90,000
    Source: Arkopharma
    Co-investigators: Barbara Gross Research unit
    Progress: Completed
  • Title: A randomised controlled trial of Phytosoya vaginal gel versus KY jelly for the management of vaginal atrophy
    Year: 2005- 06
    Amount: $50,000
    Source: Arkopharma
    Co-investigators: International group
    Progress: Completed
  • Title: A randomised controlled trial of 30 plus, versus placebo for the management of PMT.
    Year: 2005- 2009
    Amount: $150,000
    Source: SciNat
    Co-investigators: nil
    Progress: abandoned
  • Title: The effect of Periparatide compared with Risedronate on back pain in postmenopausal women with osteoporotic fractures
    Year: 2006-
    Source: Eli Lilly
    Amount: $108,000
    Co-investigators: International group
    Progress: completed
  • Title: A randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of transdermal testosterone (300mcg/day) in naturally menopausal women with hypoactive sexual desire disorder receiving systemic transdermal estrogen therapy (ADORE)
    Year: 2006-2008
    Source: Parexel
    Amount: $97,335
    Co-investigators: International group
    Progress: completed
  • Title: A randomised, open-label, comparative, multicentre trial to evaluate contraceptive efficacy, cycle control, safety and acceptability of a monophasic COC containing 2.5mg nomegestrol acetate (NOMAC) and 1.5mg E2 compared to a monophasic COC containing 3mg drospirenone and 30ug ethinyl estradiol (SAMBA).
    Year: 2006-2008
    Source: Organon
    Amount: $93,423
    Co-investigators: International group
    Progress: Completed
  • Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-center, 52-week study to evaluate the efficacy and safety of transdermal patches delivering 150 or 300 μg/day testosterone in menopausal women with low libido not receiving systemic estrogen or estrogen progestin therapy.
    Year: 2004-2008
    Amount: $105,000
    Source: Icon Clinical Research
    Co-Investigators: International group
    Progress: Completed
  • Title: A comparison of the efficacy and safety of arzoxifene versus raloxifene in postmenopausal women with osteoporosis
    Year: 2006-2009
    Amount: $30,432
    Source: Eli Lilly
    Co-Investigators: International group
    Progress: Completed
  • Title: A phase 2b multicentre, double-blind, placebo-controlled, parallel group, dose-ranging study evaluating the efficacy and safety of PD0299685 for the treatment of moderate to severe vasomotor symptoms associated with menopause.
    Year: 2006-8
    Amount: $99,300
    Source: Eli Lilly
    Co-Investigators: International group
    Progress: completed
  • Title: A two year multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment of osteoporosis in men
    Year: 2008-2010
    Amount: $ 15,000
    Source: Novartis
    Progress: completed
  • Title: A multicentre, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associated symptoms in otherwise healthy women after 6 cycles of treatment
    Year: 2008-2010
    Amount: $15600
    Source: Bayer Health Care
    Progress: finished
  • Title: A multicentre, double-blind study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contraceptive containing ethinylestradiol and levonorgestrel (Microgynon 30ED) over 6 treatment cycles on alleviating complaints of reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use
    Year: 2008-2010
    Amount: $60000
    Source: Bayer Health Care
    Progress: finished
  • Title: A double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene/Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women
    Year: 2009-2010
    Amount: $82200 ($ 8220/completed subject X 7 subjects)
    Source: Pharmaceutical sponsored – Wyeth
    Progress: finished
  • Title: A pilot, randomised, open-label, comparative study to evaluate the safety, tolerability and efficacy of lactoferrin and IgG capsules with topical lactoferrin gel compared to active placebo capsules with topical acyclovir in the treatment of herpes labialis
    Year: 2009-2011
    Amount: $44410
    Source: Probiotec Ltd
    Progress: completed
  • Title: A pilot, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Lactoferrin liquid for the treatment of influenza
    Year: 2009-2011
    Amount: $40800
    Source: Pharmaceutical sponsored – Probiotec Ltd
    Progress: completed
  • Title: A study to define the pharmacokinetic properties of lignocaine gel applied topically on a surgical field
    Year: 2009-2011
    Amount: $40566.20
    Source: Medortus Inc
    Progress: completed
  • Title: The use of complementary and alternative medicines among four ethnic groups of menopausal women living in Sydney: Implications for healthcare policy
    Year: 2010-2012
    Amount: $298,549
    Source: ARC Linkage Grant
    Progress: Requested-rejected
  • Title: A two year multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous bisphosphonate
    Year: 2008-2010
    Amount: $21000
    Source: Novartis Pharmaceuticals
    Progress: finished
  • Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of 4-Weeks Treatment with AUS-131,(S-Equol) on Vasomotor Symptoms in Menopausal Patients
    Year: 2010-11
    Amount: 150,243
    Source: Ausio Pharmaceuticals
    Progress: ongoing
  • Title: Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonogestrel subdermal implant over 12 months of use in women 18 to 35 years of age
    Year: 2011-14
    Amount: $30,880
    Source: Bayer Health Care
    Progress: commenced
  • A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis
    Sponsor: Amgen
    Estimated total income from study: $212,722
    Years for study: 2012-2014
    Status of study: start in June 2012
  • A multicentre, randomised, double-blinded, placebo-controlled, parallel group, multiple dose, study of the efficacy of 8.75 mg flurbiprofen spray in the relief of sore throat due to upper respiratory tract infection (Protocol TH1124)
    Sponsor: Reckitt Benckiser
    Estimated total income from study: $2140/subject (target 65 patients)
    Years for study: 2012
    Status of study: commenced
  • Attitudes and experience of menopause among Macedonian menopausal women living in South Eastern Sydney and the Illawarra area
    Sponsor: applied to RHW Foundation
    Status of study: completed
  • A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis
    Sponsor: Amgen
    Start date: Sep 2012
    Estimated total income from study: $36,000
    Status of study: completed
  • PROPOSED MULTICULTURAL PROJECT: Attitudes and experience of menopause among Macedonian menopausal women living in South Eastern Sydney and the Illawarra area
    Sponsor: Multicultural Health Service
    Start date: Sep 2013
    Fund: $25,000
    Status of study: completed
  • A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain
    Sponsor: AbbVie Pty Ltd
    Start date: Sep 2013
    Estimated total income from study: $113,584
    Status of study: completed
  • A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder
    Sponsor: ASTELLAS PHARMA EUROPE B.V.
    Start date: Dec 2013
    Estimated total income from study: $70,708
    Status of study: completed
  • A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron OCAS Compared to Solifenacin Succinate and Mirabegron OCAS Monotherapy in Subjects with Overactive Bladder
    Sponsor: ASTELLAS PHARMA EUROPE B.V.
    Start date: Dec 2013
    Estimated total income from study: $48,000
    Status of study: completed
  • Extension study to evaluate the long-term safety and efficacy of Elagolix in subjects with moderate to severe endometriosis-associated pain.
    Sponsor: AbbVie Pty Ltd
    Start date: July 2014
    Estimated total income from study: $50,000
    Status of study: completed
  • A randomized, parallel-group, double-blind, double-dummy, active-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Sponsor: Bayer
    Start date: Nov 2017
  • Estimated total income from study: $12,000/ completed patients (total 6 subjects)
    Status of study: Ethics approved
  • An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain
    Sponsor: PRA
    Start date: Nov 2017
  • Estimated total income from study: $15,959/ completed patients (total 4 subjects)
    Status of study: Ethics approved

Societies

Membership

  1. Society for Endocrinology (UK).
  2. International Society of Reproductive Medicine.
  3. Australian Fertility Society.
  4. Australasian Menopause Society.
  5. International Society of Gynaecological Endocrinology.
  6. Australian and New Zealand Bone and Mineral Society.
  7. Endocrine Society of Australia
  8. International Menopause Society.
  9. Australian Gynaecological Endoscopy Society.
  10. North American Menopause Society
  11. American Society for Reproductive Medicine.
  12. Australian New Zealand Breast Cancer Trials Group.
  13. Australian Society for Paediatric and Adolescent Gynaecology.
  14. Asia Pacific Menopause Federation.

Participation in professional societies

  1. Editor of "Changes", the Australasian Menopause Society's magazine, 1991-2003
  2. Committee member Australasian Menopause Society, 1992-2003
  3. Committee member NSW state committee Royal Australian College of Obstetricians and Gynaecologists, 1993- 1997
  4. Reviewer for Maturitas, journal for the International Menopause Society, 1994 -
  5. Reviewer for Clinical Endocrinology, 1994
  6. NH&MRC assessor 1994-
  7. RACOG member on the Pharmaceutical Benefits Advisory Committee on Osteoporosis, 1995.
  8. Member of the scientific committee for the organising committee of the 8th International Menopause Society Meeting, Sydney 1996.
  9. Anti-Cancer Council of Victoria assessor, 1996-
  10. RACOG appointee on the Australian Pharmaceutical Manufacturers Association Complaints Committee, 1996
  11. Reviewer for the Lancet, 1996
  12. National advisor for the Breast Cancer Institute, 1996
  13. External reviewer for the Cochrane Collaboration Menstrual Disorders Group 1996- present
  14. Reviewer for International Journal of Cancer, 1997
  15. Reviewer for the Medical Research Council (Britain), 1997
  16. Reviewer for the Australian Journal of Nutrition and Dietetics, 1997
  17. Reviewer for Diabetologia, 1997
  18. Reviewer for Menopause Digest, 1998
  19. Reviewer for American Journal of Obstetrics and Gynecology, 1998
  20. Reviewer for the Medical Journal of Australia, 1998-
  21. Reviewer for Climacteric, 1998-present
  22. Reviewer for Cancer Foundation of Western Australia, 1998
  23. Reviewer, Australian Medicines Handbook, 1998.
  24. Member of the examination committee of the Reproductive Endocrine and Infertility subcommittee of the RANZCOG (early 1990s).
  25. Member of the Scientific Committee of the 9th International Menopause Society, Yokohama, Japan, 1999.
  26. Committee member of Working party of the North American Menopause Society examining the role of isoflavones on menopausal health. 2000.
  27. Media committee, Australasian Menopause Society, 2000-
  28. Executive council member of NEDA (National Estrogen Deficiency Awareness) - an international body which aims to educate women about menopause.
  29. Member of the scientific committee of the Australian Osteoporosis Campaign
  30. Member of the AMA committee on complimentary medicine, 2001
  31. Member of the Editorial Board, Australiasian Journal Of Integrative Medicine, 2000-
  32. Reviewer for The Wellcome Trust, UK. 2000
  33. Reviewer for the Journal of the North American menopause Society, 2000-
  34. Board member on the Editorial Advisory Board of the Australiasian Journal of Integrative Medicine. 2001.
  35. Reviewer for the South African National Research Foundation, 2002
  36. Reviewer for Urological research, 2004
  37. Reviewer for Australian Family Physician 2004
  38. Reviewer for the Journal of complementary medicine 2004-
  39. Referee for Clinical Endocrinology, 1995, 2010
  40. Anti-Cancer of Victoria assessor, 1996
  41. Reviewer for the South African National Review Board, 2002.
  42. Reviewer for the Wales (UK) Office of Research and Development for Health and Social Care (WORD) Research Funding Scheme 2007.
  43. Reviewer for Thomson Reuters, 2009.
  44. Contributor to Menopause Live, the weekly internet-based service for members of the International Menopause Society. 2009-
  45. ARC assessor 2010-16
  46. Guest editor for “Pharmaceuticals” 2010, series on “Hormone Therapy”.
  47. Member scientific committee, 13th World Congress on Menopause, Roma, June 8-11 2011.
  48. Member for the scientific subcommittee on ovarian and uterine cancer for the 14th World Congress on Menopause, Calcun, Mexico 2014.

Government Committees

  1. NSW government Health Claims and Consumer Protection Advisory Committee (Health Commission), 2002
  2. Federal Government committee examining the Pan Pharmaceutical investigation, 2003
  3. NSW Government committee on the regulation of complimentary health practitioners, 2004
  4. Cancer Institute NSW working party on complementary therapies, 2004-2007
  5. Board member PCOS Australian Alliance, 2010-11 – a strategic advisory group under the auspices of the Jean Hailes Foundation for Women’s Health. This group has been set up to derive management recommendations for women with PCOS.
  6. Member of the Management of women with breast cancer with an identified gene fault or at high risk of a gene fault Working Group for Cancer Australia (Australian government). 2012

Publications in major journals

A. Full papers in refereed journals

  1. Eden JA (1987). Fetal induced trauma as a cause of antepartum haemorrhage. American Journal of Obstetrics and Gynecology, 157, 830-1.
  2. Eden JA & Place J (1988). Accidental haemorrhage? British Journal Radiology, 61, 540.
  3. Eden JA (1988). Sustained effects of oestrogen implant overdosage. Lancet,ii,161.
  4. Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME (1988). What are the ultrasound and biochemical features of impending ovulation? Australian and New Zealand Journal of Obstetrics and Gynaecology, 28, 225-7.
  5. Eden JA, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME (1988). Factors influencing the free androgen index in a group of subfertile women with normal ovaries. Annals of Clinical Biochemistry, 25(4),350-3.
  6. Eden JA (1988). Can the fetus cause placental separation? Australian and New Zealand Journal of Obstetrics and Gynaecology, 28,119-20.
  7. Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J & Pawson M (1988). Elevated free androgen index is an indicator of polycystic ovaries in oligomenorrhoea without obesity or hirsuties. Annals of Clinical Biochemistry, 25(4), 346-9.
  8. Eden JA (1988). Which is the best test to detect the polycystic ovary? Australian and New Zealand Journal of Obstetrics and Gynaecology, 28, 221-4.
  9. Eden JA, Carter GD, Jones J, Alaghband-Zadeh J (1988). A comparison of follicular fluid levels of insulin-like growth factor 1 in normal dominant and cohort follicles, polycystic and multicystic ovaries. Clinical Endocrinology, 29,327- 36.
  10. Eden JA (1989). Two cases of partial 21 hydroxylase deficiency associated with progesterone excess. Australian and New Zealand Journal of Obstetrics and Gynaecology, 29,268- 70.
  11. Eden JA, Place J, Jones J, Carter GD, Alaghband-Zadeh J, Pawson ME (1989). The effect of clomiphene citrate on endometrial and uterine growth. Obstetrics and Gynecology, 73(2), 187-90.
  12. Eden JA, Carter GD, Jones J, Alaghband-Zadeh J (1989). Insulin-like growth factor 1 as an intra-ovarian hormone - an integrated hypothesis and review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 29,30-7.
  13. Eden JA, Place J (1989). The prevalence of polycystic ovaries in thin, oligomenorrhoeic, anovulatory women. Australian and New Zealand Journal of Obstetrics and Gynaecology, 29,70-1.
  14. Eden JA, Place J, Carter GD, Alaghband-Zadeh J, Pawson ME (1989). Is the polycystic ovary a cause of infertility in ovulatory women? Clinical Endocrinology, 30,77-82.
  15. Eden JA, Place J, Carter GD, Alaghband-Zadeh J, Pawson ME (1989). The role of chronic anovulation in the polycystic ovary syndrome - normalization of sex-hormone binding globulin levels after clomiphene induced ovulation. Clinical Endocrinology, 30,323-332.
  16. Eden JA, Place J (1989). Ultrasound can reliably detect the polycystic ovary- a simple method for establishing an ovarian scanning service. British Journal of Radiology, 62, 656.
  17. Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME (1989). The diagnosis of polycystic ovaries in subfertile women. British Journal of Obstetrics and Gynaecology, 96, 809-15
  18. Eden JA (1989) The polycystic ovary syndrome - a review. Australian and New Zealand Journal of Obstetrics and Gynaecology, 29, 403-16.
  19. Eden JA, Jones J, Carter GD, Alaghband-Zadeh J (1990). Follicular fluid concentrations of insulin-like growth factor 1, epidermal growth factor, transforming growth factor-alpha and sex steroids in volume matched normal and polycystic human follicles. Clinical Endocrinology, 32 (4), 395-406.
  20. Holly JMP, Eden JA, Alaghband-Zadeh J, Carter GD, Jemmott RC, Cianfarani S, Chard T, Wass JAH (1990). Insulin-like growth factor binding proteins in follicular fluid from normal dominant and cohort follicles, polycystic and multicystic ovaries. Clinical Endocrinology, 33 (1), 53-64.
  21. Eden JA (1990). Too much of a good thing? Two cases of oestrogen overdosage associated with oestradiol implants. Medical Journal of Australia, 152, 558.
  22. Eden JA. The Hazards of Amenorrhoea (1991). Medical Journal of Australia, 154, 536-542.
  23. Eden JA (1991). The polycystic ovary syndrome presenting as resistant acne, successfully treated with cyproterone acetate. Medical Journal of Australia, 155, 677-680.
  24. Eden JA (1992). Progestogens - An occasional review. Asia-Oceania Journal of Obstetrics and Gynaecology, 17 (4), 289-295.
  25. Eden JA (1992). Hormone replacement and osteoporosis. Patient Management, 41-44.
  26. Eden JA (1992). Oestrogen and the Breast - 1. Myths about oestrogen and breast cancer. Medical Journal of Australia, 157(3),175-7.
  27. Eden JA (1992). Oestrogen and the Breast - 2. The management of the menopausal woman with breast cancer. Medical Journal of Australia, 157 (4), 247-50.
  28. Eden JA (1993) Estrogen and the breast. Menopause Digest, 28-30.
  29. Eden JA, Bush T, Nand S, Wren G (1995). A case-controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer. Menopause, 2(2), 67-72.
  30. Eden JA (1993). Menopause before 40 - premature, but not always permanent. Australian and New Zealand Journal of Obstetrics and Gynaecology, 33, 201-3.
  31. Jahanfar S, Eden JA (1993) Idiopathic hirsutism or polycystic ovary syndrome? Australian and New Zealand Journal of Obstetrics and Gynaecology, 33(4),414-416.
  32. Jahanfar S, Garrett DK, Eden JA (1994). A comparison between monoclonal and polyclonal assays of luteinizing hormone in polycystic ovary syndrome. Australian Journal of Medical Sciences, 15, 14-17.
  33. Eden JA, Holly JMP, Alaghband-Zadeh J, Carter GD, Jones J (1994). A study of the relationship between follicular fluid levels of insulin-like growth factor binding protein-1 (IGFBP-1) and sex steroids from normal human follicles. Gynaecological Endocrinology, 7(3), 153-158.
  34. Eden JA (1994). Massive ovarian oedema: a case report and literature review. British Journal of Obstetrics and Gynaecology, 101(5), 456-6.
  35. Eden JA (1995). Hormone replacement therapy - replacement for a hormone deficiency or unnatural meddling? Current Therapeutics, 36(1), 16-18.
  36. Eden JA (1995). Hormone replacement and osteoporosis. Current Therapeutics, 36 (2), 52-55.
  37. Eden JA (1995). Hormone therapy and osteoporosis. Patient Management, 24(11), 41-5.
  38. Jahanfar S, Eden JA, Warren P, Seppala M, Nguyen T (1995). A twin study of polycystic ovary syndrome. Fertility and Sterility, 63, 478-486. (this paper attracted an editorial, Fertility & Sterility, 63(2), 953-4.)
  39. Jahanfar S, Eden JA (1995). Bulimia nervosa and polycystic ovary syndrome. Gynecological Endocrinology, 9, 113-7.
  40. Eden JA (1995). Polycystic ovary syndrome. Gynaecological Snapshot, 3 (2), 10-13.
  41. Knight DC, Eden JA (1995). Phytoestrogens - a short review. Maturitas, 22,167-175.
  42. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2(2): 67-72
  43. Dew JE, Eden JA (1995). Gynaecological complications of women treated with tamoxifen for breast cancer. Australian & New Zealand Journal of Obstetrics & Gynaecology, 35(2), 198-200.
  44. Eden JA (1995). Should women who have had breast cancer take hormone replacement therapy? Maturitas, 22 (2), 69-70.
  45. Eden JA (1996). Estrogen replacement in survivors of breast cancer: A risk-benefit assessment. Drugs and Ageing, 8(2), 127-133.
  46. Eden JA (1996). A case-controlled study of combined continuous estrogen-progestin replacement therapy amongst women with a personal history of breast cancer. Menopause Digest,1, 25-7.
  47. Wren BG, Eden JA (1996). Do progestogens reduce the risk of breast cancer? A review of the evidence. Menopause, 3, 4-12.
  48. Eden JA (1996). Hormonal therapy and osteoporosis. New Ethicals, May 1996 (supplement), 13-15.
  49. Knight DC, Wall PL, Eden JA (1996). A review of phytoestrogens and their effects in relation to menopausal symptoms. Australian Journal of Nutrition 53, 5-12.
  50. Knight DC, Eden JA (1996). Phytoestrogens - a review of the human literature. Obstetrics and Gynecology, 87(5, part 2), 897-904.
  51. Jahanfar S, Eden JA (1996). Genetic and non-genetic theories on the aetiology of polycystic ovary syndrome. Gynecological Endocrinology, 10,357-364.
  52. Eden JA, Wren BG (1996). Hormone replacement therapy after breast cancer - a review. Cancer Treatment Reviews 22,335-343.
  53. Eden JA (1997). Hormone replacement after breast cancer and a review of the therapeutic properties of phytoestrogens. Gynecological Endocrinology (supplement 1), 11, 37-42.
  54. Jahanfar S, Nguyen T, Eden JA, Wang XL, Wilcen DEL (1997). A twin study of polycystic ovary syndrome and lipids. Gynaecological Endocrinology 11 (2), 111-118.
  55. Eden JA (1997). Polycystic ovary syndrome. Gynaecological Forum; 2(2): 5-7.
  56. Eden JA (1997). Menopausal symptoms during chemotherapy for breast cancer. Current therapeutics, 38,25-7.
  57. Ogen/Provera study group. Menopausal symptom control and side-effects on continuous estrone sulphate and three doses of medroxyprogesterone acetate. Climacteric, 1998, 1, 211-218.
  58. Eden JA (1998). Hirsutism. Australian Pharmacist. 17(2), 80-3.
  59. Mackey R, Eden JA (1998). Phytoestrogens. Journal of the British Menopause Society, 4 (1), 18-25.
  60. Mackey R, Eden JA (1998). Phytoestrogens and the menopause. Climacteric , 302-308.
  61. Dew J, Eden JA et al (1998). A cohort study of hormone replacement after breast cancer. Climacteric 1,137-42.
  62. Eden JA. Menopause after breast cancer (1999). Menopause Digest 2, 6-7.
  63. Eden JA (1999). Management of menopausal symptoms after breast cancer. Gynaecology Forum, 4, 14-15.
  64. Knight DC, Howes J, Eden JE (1999). The effect of Promensil, an isoflavone extract, on menopause symptoms. Climacteric 2, 79-84.
  65. Eden JA, Warren P (1999). A review of 1,019 consecutive cases of polycystic ovary syndrome demonstrated by ultrasound. Australasian Radiology, 43, 41-6.
  66. Eden JA. Managing menopause - HRT or herbal? Modern Medicine 1999, August, 32-5.
  67. Verheul HAM, Coelingh-Bennink HJT, Kenemans P, Atsma WJ, Burger CW, Eden JA, Hammar M, Marsden J, Purdie DW. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas (2000), 36, 1-17.
  68. Eden JA (2000). Can we alter breast cancer risk? Climacteric, 3 (supplement 1): 22-26.
  69. Wren BG, McFarland K, Edwards L, O’Shea P, Sufi S, Gross B, Eden JA. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000, 3:155-160.
  70. Howes JB, Sullivan D, Lai N, Nestel P, Pomeroy S, West L, Eden JA, LG Howes (2000). The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profile of postmenopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 152, 143-7.
  71. Eden JA. Diet, phytoestrogens, and the prevention of breast cancer. Journal of the North American Menopause Society (2000), 7(5), 283-5.
  72. Mackey R, Ekangaki A, Eden JA (2000). The effects of soy protein in women and men with elevated plasma lipids. Biofactors 12:251-257.
  73. Knight DC, Howes JB, Eden JA, Howes LG (2001). The effects and acceptance of isoflavone containing soy powder dietary supplementation on menopausal symptoms. Climacteric 4, 13-18.
  74. Eden JA. Herbals for menopause – do they work and are they safe? Medical Journal of Australia 2001; 174 (2):63-64
  75. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone containing soy powder dietary supplementation. Climacteric 2001, 4 (1), 13 -- 8.
  76. Eden JA (2001). Managing the menopause - phytoestrogens or HRT? Annals of medicine 33: (4-6
  77. Evans V, Millar TJ, Eden JA, Wilcox MD. Menopause, hormone replacement therapy and tear function. Advances in experimental medicine and biology 2002, 506 (part B), 1029 -33.
  78. Eden JA. Managing the menopause. Journal of Complimentary Medicine 2002; 1(2):53-7.
  79. Eden JA. Safety of hormone replacement therapy after mastectomy. Medical Journal of Australia 2002, 176 (12), 617-8.
  80. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer. Climacteric 2002; 5(2): 151-5.
  81. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Medical Journal of Australia 2002, 177, 347-51.
  82. Durna EM, Crowe SM, Leader LR, Eden JA. Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. Climacteric 2002, 5, 266-276.
  83. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated the breast cancer. Climacteric. 2003, 6 (1), 45-42.
  84. Willetts KE, Ekangaki A, Eden JA. Effect of ginger extract on pregnancy-induced nausea: a randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology 2003; 43 (2):139-44
  85. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods and quality of life for postmenopausal women. Menopause: The Journal of the North American Menopause Society, 2003, 10(1):13-8.
  86. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen – a pilot study. Climacteric 2003; 6:347-53.
  87. Costello MF, Eden JA. A systematic review of the reproductive effects of metformin in patients with PCOS. Fertility and Sterility, 2003; 79 (1): 1-13.
  88. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA (2003). Serenoa repens extract for benign prostate hyperplasia: a randomised controlled trial. British Journal of Urology, 92, 267-270.
  89. Eden J. Progestins and breast cancer risk. American Journal of Obstetrics and Gynecology 2003; 188(5): 1123-31.
  90. Davis SR, O’Neill SM, Eden JA et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium – a pilot study. Journal of the North American Menopause Society 2004; 11(2):167-75.
  91. Durna EM, Heller GZ, Leader LR, Sjoblom P, Eden JA, Wren BG. Breast cancer in premenopausal women: recurrence in survival rates and relationship to hormone replacement therapy. 2004. Climacteric. 2004, 7(3), 284-91.
  92. Eden JA. Progestins and breast cancer risk. Menopause management. 2004, 13 (2), 12-17
  93. Davis SR, O’Neill SM, Eden J et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium: a randomised controlled trial. Menopause 2004; 11(2):167-75.
  94. Eden J. The need for tissue selective menopausal agents. Gynecological Endocrinology 2005; 21(Supplement 1):22-27.
  95. Yaffe M, Hendrix S, Pike M, Santen R, Eden J Genazzani A. Is mammographic density as currently measured, a robust surrogate marker for breast cancer? Gynecological Endocrinology 2005; 21 (supplement 1): 17-21
  96. Peeyananjarassri K, Cheewadhanaraks S, Hubbard M, Manga RZ, Manocha R, Eden J. Menopause symptoms in a hospital-based sample of women in southern Thailand. Climacteric 2006; 9:23-29.
  97. Lu J, Liu J, Eden J. The experience of menopausal symptoms by Arabic women in Sydney. Climacteric 2007; 10:72-79
  98. Liu J, Eden J. Experience and Attitudes toward Menopause in Chinese Women Living in Sydney – A Cross Sectional Survey.Maturitas2007; 58(4):359-365.
  99. Eden JA. Tibolone for postmenopausal women. O and G magazine 2007; 9:13-14.
  100. Hafiz I. Liu J, Eden J. A quantitative analysis of the menopause experience of Indian women living in Sydney. Australian and New Zealand Journal of Obstetrics and Gynaecology 2007; 47(4):329-334.
  101. El-Hage G, Manga RZ, Eden JA. A double-blind, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomised women with hypoactive sexual desire disorder. Climacteric 2007; 10: 335-343.
  102. Costello MF, Shrestha B, Eden J, Johnson, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Human Reproduction 2007; 22(5):1200-1209.
  103. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with bioidentical hormone replacement therapy. Medical Journal of Australia 2007; 187 (4): 240-1
  104. Liu J, Eden JA. The menopause experience of Greek women in Sydney. Menopause – the Journal of the North American Menopause Society 2008; 15(30): 476-81.
  105. Eden JA. Human breast cancer stem cells and sex-hormones – a narrative review. Menopause: The Journal of the North American Menopause Society 2010; 17 (4): 801-810.
  106. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden A et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010; 13: 121-31.
  107. Eden JA. Does mammography reduce breast cancer mortality? Climacteric 2010; 13 (4): 400-1.
  108. Eden JA. Breast cancer, stem cells and sex hormones: part 1 – the impact of fetal life and infancy. Maturitas 2010; 67(2): 117-120.
  109. Eden JA. Breast cancer, stem cells and sex hormones: part 2 - the impact of the reproductive years and pregnancy. Maturitas 2010; 67(3): 215-218.
  110. Eden J. Why does oestrogen-only hormone therapy have such a small impact on breast cancer risk? A hypothesis. GYNECOLOGICAL ENDOCRINOLOGY 27 (3): 170-175 MAR 2011
  111. Eden JA. Breast cancer, stem cells and sex hormones: part 3 - the impact of the menopause and hormone replacement. Maturitas 2011; 68(2): 129-136 (invited 3-part review)
  112. O’Neill S, Eden J. Pathophysiology of menopause symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2012; 22 (4): 63-9 (invited review)
  113. Eden J, O’Neill S. The management of perimenopausal menstrual symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2012; 22 (4): 98-101 (invited review)
  114. Eden JA. Phytoestrogens for menopausal symptoms: a review. Maturitas 2012; 72 (2): 157-159
  115. Eden JA. Menopausal status, adipose tissue, and breast cancer risk: impact of estrogen replacement therapy. Hor Mol Bio Clin Invest 2013 (in press)
  116. A new mother with night sweats. Medicine Today 2013; 14 (4): 67-68.
  117. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for vasomotor symptoms (review). The Cochrane Collaboration 2013. Cochrane Review ID: 541999090611595730
  118. Vitex agnus castus and premenstrual syndrome. Medicine Today 2013; 14(10):400-1
  119. Polycystic Ovary Syndrome. Medical Observer. 2014 (in press)
  120. Eden J, O’Neill S. The management of perimenopausal menstrual symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2014, DOI: 10.1016/j.ogrm.2014.05.004
  121. O’Neill S, Eden J. Pathophysiology of menopause symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2014
  122. Managing menopausal symptoms. Medical Observer, 30 May 2014: 19-24
  123. Eden JA. DHEA replacement for postmenopausal women: placebo or panacea? Climacteric 2015; 18(4): 439-40.
  124. Eden J. Managing menopausal symptoms after breast cancer. European Journal Of Endocrinology, 2016 Mar, Vol.174(3), pp.R71-R77
  125. Golebiowski, B, Badarudin, N, Eden, J, Liu, J, Raisin, L, Williams, J, Hampel, U, You, JJ, Stapleton, F The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. Br J Ophthalmol bjophthalmol-2016-309498Published Online First: 3 November 2016 doi:10.1136/bjophthalmol-2016-309498
  126. Golebiowski, B, Badarudin, N, Eden, J, Liu, J, Raisin, L, Williams, J, Hampel, U, You, JJ, Stapleton, F. Does endogenous serum oestrogen play a role in meibomian gland dysfunction in postmenopausal women with dry eye? Br J Ophthalmol 2016;0:1–5. doi:10.1136/bjophthalmol-2016-308473
  127. Golebiowski, B, Badarudin, N, Eden, J, Liu, J, Raisin, L, Williams, J, Hampel, U, You, JJ, Stapleton, F. Randomised, placebo-controlled, pilot study of the effects of transdermal testosterone and oestrogen therapy on dry eye in post-menopausal women. British Journal of Opthalmology 2016; 0:1-7
  128. Strezova, A, O’neill, S, O’callaghan, C, Perry, A,Liu, J, Eden, J. Cultural issues in menopause: an exploratory qualitative study of Macedonian women in Australia. Menopause 2016; 24 (3): (in press)
  129. Eden J. The endometrial and breast safety of Menopausal Hormone Therapy containing micronized progesterone: a short review" (ANZJOG-2016-0285.R1) in press
  130. Eden J. Important New Developments in Hormone Replacement Therapy Body-Identical HRT: Micronised Progesterone Is Finally Available in Australia. HealthEd, 2017
  131. Eden J. Vaginal atrophy and sexual health. HealthEd, 2017
  132. Eden J. Body Identical Hormone therapy. O and G magazine 2017.
  133. Eden J, O’Neill S. The management of perimenopausal menstrual symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2017, in press
  134. O’Neill S, Eden J. Pathophysiology of menopause symptoms. Obstetrics, Gynaecology and Reproductive Medicine 2017, in press.
  135. Eden JA. The endometrial and breast safety of menopausal hormone therapy containing micronized progesterone: A short review. ANZJOG 2007; 57: 12-15
  136. Golebiowski B, Badarudin N, Eden J et al. Does endogenous serum oestrogen play a role in Meibomian gland dysfunction in postmenopausal women with dry eye? Br J Ophthalmol 2017; 101:218-222.

B. Abstracts

All my talks given below had an abstract as well

Blanka Golebiowski, Noor Badarudin, John Eden, Fiona Stapleton. EFFECTS OF TESTOSTERONE AND ESTROGEN THERAPY ON DRY EYE IN POST-MENOPAUSAL WOMEN: A PILOT STUDY. School of Optometry and Vision Science, University of New South Wales. Barbara Gross Research Unit RHW, UNSW. American Academy of Optometry meeting ( November 2014).

C. Books

  1. Womens Hormone Problems, an 80 page book for undergraduates and general practitioners. (Three editions - 48,000 sold).
  2. PCOS – a woman’s guide to identifying and managing PCOS. Allen and Unwin. 2005
  3. True Lies – Getting over past hurts. How to let go of emotional pain before it eats you alive! 2010.

D. Chapters in Books

  1. Eden JA (1991). Dysmenorrhea and Premenstrual Syndrome. In, Essentials of Obstetrics and Gynecology, Vol 2 (Hacker & Moore eds), WB Saunders Co, Philadelphia.
  2. Eden JA. Hirsutism. In, Progress in Obstetrics and Gynaecology (Ed Studd JWW) 1991 (9), Churchill Livingstone, London, 319-34.
  3. Eden JA. Androgenic disorders and the Menopause. The Clinical Management of Sex Hormone Deficiency: Eds Wren BG, Nachitgall L. McGraw Hill, Sydney 1996, 32-40.
  4. Eden JA. Hormone replacement therapy and cancer. The Clinical Management of Sex Hormone Deficiency: Eds Wren BG, Nachitgall L. McGraw Hill, Sydney 1996, 126-133.
  5. Eden JA. Hormone replacement therapy and breast cancer. The Clinical Management of Sex Hormone Deficiency: Eds Wren BG, Nachitgall L. McGraw Hill, Sydney 1996, 134-140.
  6. Eden JA (1995). The use of hormone replacement therapy in women previously treated for breast cancer. Contemporary Reviews in Obstetrics and Gynaecology (Eds Chamberlain G, Drife J). Parthenon Publishers. Volume 7, 20-24.
  7. Eden JA. Gynaecological Endocrinology. Handbook of Obstetrics and Gynaecology, 4th edition (Eds Leader LR, Bennett MJ, Wong F). Chapman and Hall Medical, Melbourne, 1996, 361-382.
  8. Eden JA (1996). Hormone Replacement after breast cancer. American Society of Clinical Oncology Educational Book, Bostrom Corporation, 187-9.
  9. Eden JA. Hormone replacement therapy after breast cancer. Progress in Reproductive Medicine (Eds Studd J, Asch R), Parthenon Publishers.
  10. Eden JA (1996). Polycystic ovary syndrome. Surgical Pathology of the Ovaries. Second Edition. (Eds Russell P, Farnsworth A), Churchill Livingstone Publishers.
  11. Eden J. Therapeutics - cancer of the reproductive organs. Breast. Oestrogen and Progestogens in Clinical Practice. First edition. Churchill Livingstone Publishers .
  12. Eden JA (1998). Phytoestrogens and the Menopause. In, Phytoestrogens (Ed Adlercreutz H.), Bailliere’s Clinical Endocrinology and Metabolism, 581-8.
  13. Prescribing HRT in the presence of known gynaecological problems. In, Current opinion on the management of the menopause.
  14. Management of menopausal symptoms after breast cancer (2000). Management of the Menopause in the Millennium. (Ed JWW Studd), Parthenon Publishing, 221-4.
  15. Menopause. In, General Practice: the integrative approach. Phelps and Hassed, Elsevier press 2011.
  16. Breast cancer risk: role of somatic breast stem cells. In, Stem cells and cancer stem cells. Hayat MA, Springer Press, 2011.
  17. Managing the Menopause 2015. Cambridge University Press. Eds Panay, Briggs, Kovacs. Chapter 14 Gynecological pathology in the menopause (excluding cancers)
  18. Eden JA. Hormone replacement therapy.2015 In, The Wiley-Blackwell Encyclopedia of Gender and Sexuality Studies.

E. Letters to the Editor

  1. Eden JA (1992). Oestrogen and the Breast. Medical Journal of Australia, 157,571.
  2. Eden JA (1992). Oestrogen and the Breast. Medical Journal of Australia, 157, 643.
  3. Eden JA (1992). Oestrogen and the Breast. Medical Journal of Australia, 157,838-40.
  4. Wren BG, Webster M, Eden J (1992). Management of hyperlipidaemia - a consensus statement. Comment on: Medical Journal of Australia,156, 510.
  5. Eden JA (1994). Ovarian biopsy and premature menopause. British Journal of Obstetrics and Gynaecology, 101, 925.
  6. Eden J (1998) Phytoestrogen study design. Climacteric, 1998, 243-4.

F. Other Articles

  1. Eden JA (1996). How to treat - the Menopause. Australian Doctor, 15 March 1996 (8 page "lift-out" section).

Web-based contributions

  1. Established www.whria.com.au (see patient downloads)
  2. Herbals for climacteric symptoms and risk of breast cancer. Menopause Live for International Menopause Society
  3. WHRIA website: www.WHRIA.com.au
  4. “Perimenopause” on CREI web site

Invitations to International Meetings

  1. haired 2 day sponsored symposium at FIGO on the menopause and presented 2 papers on osteoporosis, Singapore: 12-22 September 1991.
  2. Hormones after breast cancer. International Menopause Society Meeting, Stockholm, 21-24 June 1993.
  3. A twin study of polycystic ovary syndrome. 3rd World Congress on Ultrasound in Obstetrics and Gynaecology, Las Vegas, Nevada, USA, 24-28 October 1993.
  4. A case controlled study of continuous combined hormone replacement therapy after breast cancer (Invited speaker). 3rd World Congress on Ultrasound in Obstetrics and Gynaecology, Las Vegas, Nevada, USA, 24-28 October 1993.
  5. The role of progestogens in hormone replacement therapy. Asia-Oceania Congress on Obstetrics and Gynaecology, Manila, the Philippines, 15-19 November 1993.
  6. Hormone replacement therapy after breast cancer. International Breast Cancer Study Group meeting, Lugarno, Switzerland, 23-25 April 1994.
  7. Hormones and breast cancer. 2nd International Symposium on Hormonal Carcinogenesis, Stockholm, 5-9 July 1994.
  8. Prevention and management of osteoporosis by HRT and calcium. 2nd International Symposium on Osteoporosis, Beijing, China (11-16 October 1995).
  9. Hormones and breast cancer & Phytoestrogens - Nature's own remedy? New Zealand Gynaecology Club meeting, Fiji, 19-22 October 1995.
  10. The Polycystic Ovary Syndrome. The Obstetrical and Gynaecological Society of Hong Kong, 20 November 1995.
  11. Overview of PCOS: pathophysiology, diagnosis & treatment. Royal College of Obstetricians and Gynaecologists of Thailand. Dermatological Society of Thailand, 22 November 1995.
  12. The Polycystic Ovary Syndrome. The Philippines Obstetrical and Gynaecological Society, 23 November 1995.
  13. Hormone replacement therapy to prevent cardiovascular disease: Which patient? Which regimen? 6th International Congress on Cardiovascular Pharmacology, 29 February 1996, Sydney.
  14. Hormone replacement after breast cancer. American Society of Clinical Oncology 32nd Annual Meeting, Philadelphia, 18-21 May 1996.
  15. Isoflavones and the menopause. Second international symposium on the role of soy in preventing and treating chronic disease. Brussels, Belgium, 15-19 September 1996.
  16. Herbs for Menopause. KK Hospital, Singapore, 25 April 1997
  17. Natural Therapies for Menopause. Obstetrics and Gynaecological Society of Singapore, 26 April 1997.
  18. Natural Therapies for Menopause. Malaysian Menopause Society, 27 April 1997.
  19. Natural Therapies for Menopause. Malaysian Obstetrics and Gynaecology Society, Penang, 28 April 1997.
  20. Alternatives to HRT. Philippines Climacteric Society, 7 September 1997.
  21. Norethisterone. Philippines Climacteric Society, 7 September 1997.
  22. Who should take long-term HRT? Singapore Gynaecology Club, 14 March 1998.
  23. Who should take long-term HRT? Taiwan Obstetrics & Gynaecology Annual Meeting, Taiwan 15 March 1998.
  24. HRT after breast cancer. Austrian Gynaecological Oncology Group, Salzburg, 18 April 1998.
  25. Phytoestrogens. International Food symposium. Tokyo, Japan, 21 May 1998.
  26. HRT, what are the options? Ovarian aging symposium, Brussels, 4 September 1998.
  27. Can we alter breast cancer risk? 16th World Congress on Fertility and Sterility, San Francisco, 3-9 October 1998
  28. Natural Therapies for Menopause. Australasian Menopause Society annual meeting, Auckland, October 1998.
  29. Menopause for diabetic women. 4th International Diabetes Federation Western Pacific Region. 25 August 1999. Sydney, Australia.
  30. Menopause after breast cancer. 9th international meeting on the Menopause, Yokohama, Japan, October 1999. (Chaired symposium).
  31. Soy for menopause. 3rd International Meeting on Soy, Washington DC, 31 October - 4 November 1999.
  32. The effects of soy protein on men and women with elevated lipids. 2nd International Conference on food factors, Kyoto, 12-17 December 1999.
  33. The effect of different HRT regimens on breast cancer risk. Wyeth-Ayerst expert panel, New York, 9 & 10 June 2000.
  34. The genetics of PCOS. XVIIth Asian and Oceanic Congress of Obstetrics and Gynaecology, July 9-14, 2000. (session convenor)
  35. The great debate – “One woman’s bread is not another woman’s patch” 1st International Congress of Endocrine Nursing, 1 November 2000.
  36. American Fertility Society, “Goodwill Mission” to China, 21-27 May 2001.
  37. HRT after breast cancer. Asian Pacific Menopause Society, 28 May 2001, Korea.
  38. The history of PCOS. International Symposium on the PCO, Melbourne, 24 November 2001
  39. HRT after breast cancer. International Menopause meeting, Berlin, 14 June 2002
  40. Testosterone cream. International Menopause meeting, Berlin, 14 June 2002
  41. The Polycystic ovary syndrome. Joint Scientific meeting of the RANZCOG and RCOG, Sydney 2 October 2002.
  42. The need for tissue-specific agents. International Gynaecological Endocrine Society, Florence, Italy, 27 February 2004.
  43. Managing menopause naturally. New Zealand branch of the RANZCOG, 14 March 2004.
  44. HRT in 2004. New Zealand branch of the RANZCOG, 14 March 2004.
  45. Osteoporosis and the gynaecologist. New Zealand branch of the RANZCOG, 14 March 2004.
  46. Hormones and Breast Cancer. FIGO (and chaired session), Kuala Lumpa, 9 November 2006.
  47. A multicultural study of the menopause experience of women living in Sydney. International Menopause Society meeting, Madrid, May 2008.
  48. A multicultural study of the menopause experience of women living in Sydney. International Menopause Society meeting, Madrid, May 2008.
  49. Breast Cancer Stem cells. Philippines Menopause Society, 17, 18 September 2009.
  50. Managing Menopause after Breast Cancer. Philippines Menopause Society, 17, 18 September 2009.
  51. Breast cancer stem cells. 14th World Congress on Gynaecological Endocrinology. Florence, Italy, 4-7 March 2010.
  52. Chair a symposium at the Asia-Pacific Menopause Federation, Sydney, 26-29 September 2010.
  53. Member scientific committee, 13th World Congress on Menopause, Roma, June 8-11 2011.
  54. “Once we know that a woman has oligomenorrhoea and hyperandrogenism, do we really need to scan the pelvis to assess for polycystic ovaries?” 23rd World Congress on Ultrasound in Obstetrics and Gynaecology, 7 October 2013

Papers Presented at Scientific Meetings

  1. The diagnosis of polycystic ovaries in non obese, non hirsute women: presented at the Society for Endocrinology meeting 19 November 1987.
  2. Fetal-induced trauma as a cause of antepartum haemorrhage: presented at the British Medical Ultrasound Meeting, 9 December 1987.
  3. The Infertile Couple: presented at a post graduate meeting, Charing Cross Hospital, 18 February 1988.
  4. The role of IGF1 in ovarian follicular function: presented at the Middlesex Hospital, 2 February 1988.
  5. The diagnosis of the Polycystic Ovary: presented at the Paddington College, London, 7 March 1988.
  6. The relationship between follicular growth and Insulin-like Growth Factor 1 (IGF1) in human follicular fluid: presented at the 7th Joint Meeting of British Endocrine Societies, in Exeter, 20 April 1988.
  7. The Polycystic Ovary Syndrome: Clinical Research Centre, Northwick Park, 18 July, 1988.
  8. The polycystic ovary - an ovarian disorder? The Middlesex Hospital, London, 18 October 1988.
  9. The role of insulin-like growth factor 1 in the selection of the dominant follicle. The Middlesex Hospital, London, 1 November 1988.
  10. What is the role of chronic anovulation in the pathophysiology of the polycystic ovary syndrome? 178th Meeting of the Society for Endocrinology: London, 16-18 November 1988.
  11. Can the polycystic ovary (PCO) cause infertility in the ovulatory woman? 178th Meeting of the Society for Endocrinology: London, 16-18 November 1988.
  12. The relationship between follicular fluid levels of insulin-like growth factor 1 (IGF1) and sex steroids in human dominant and cohort follicles. 178th Meeting of the Society for Endocrinology: London, 16-18 November 1988.
  13. Does serum insulin-like growth factor 1 (IGF1) have an endocrine role in the control of follicular function? 178th Meeting of the Society for Endocrinology: London, 16-18 November 1988.
  14. Ultrasound can reliably detect the polycystic ovary (PCO) - a simple method for establishing an ovarian scanning service. 20th British Medical Ultrasound Society Meeting: London, 6-8 December 1988.
  15. The role of IGF1 in the selection and growth of the dominant follicle. Royal Society of Medicine: 7 February 1989.
  16. The polycystic ovary contains higher follicular fluid concentrations of IGF1 than matched controls. Joint meeting of British endocrine societies (Manchester): 10-13 April 1989.
  17. Human follicular fluid does not contain significant concentrations of EGF: Joint meeting of British endocrine societies (Manchester): 10-13 April 1989.
  18. IGF1 and the dominant follicle: 5th RACOG Congress (Brisbane): 18-22 September 1989.
  19. How reliable is an ultrasound diagnosis of PCO?: 5th RACOG Congress (Brisbane): 18-22 September 1989.
  20. The PCO syndrome, St Margaret's Hospital, 25 October 1989.
  21. Dysfunctional uterine bleeding and the PCO syndrome, Newcastle Hospital, 28 March 1990.
  22. Is the Pill good for you? RHW scientific meeting, 7 April 1990.
  23. The PCO syndrome, Scientific meeting Wollongong Hospital, 11 April 1990.
  24. Symposium on Cyproterone acetate, Townsville, Queensland, 14 May 1990.
  25. The Menopause, Intercontinental Hotel, Sydney, 29 May 1990.
  26. HRT & dysfunctional uterine bleeding, Rural Doctors Network Meeting, Cooma, NSW, 11-12 August 1990.
  27. Long-term benefits of HRT, St George Hospital meeting, 19 August 1990.
  28. The PCO syndrome - an ovarian disorder? RACOG meeting, Canberra: 9 November 1990.
  29. Should all menopausal women be offered HRT? RACOG meeting, Canberra: 9 November 1990.
  30. Oestrogen replacement for the menopause - fact, fiction, fantasy. Watson Memorial Lecturer, St George Hospital. 22 November 1990.
  31. Menopause and Scleroderma, Annual meeting, Australian Scleroderma Society, Hyatt Sydney: 9 February 1991.
  32. The Perils of amenorrhoea. RACGP course, Sydney, 15 February 1991.
  33. Hazards of amenorrhoea. RHW scientific meeting, 24 March 1991.
  34. Infertility. Sydney Hospital, 1 May 1991.
  35. Management of amenorrhoea, Family medicine program course, 15 July 1991.
  36. SLE and ovarian failure, Prince of Wales Hospital, 25 July 1991.
  37. Menopause, Family medicine program course, 6 August 1991.
  38. Menopause, Rural Doctors Network meeting, Cooma, 10-11 August 1991.
  39. The Oral Contraceptive Pill, Family medicine program course, 20 August 1991.
  40. The PCO syndrome. Family Planning seminar, Canberra, 23 August 1991.
  41. Depression and the menopause, Royal North Shore Hospital meeting, "The Menopause": 31 August 1991.
  42. Menopause, Rural Doctors Network meeting, Tamworth, 3 September 1991.
  43. Chaired 2 day sponsored symposium at FIGO on the menopause and presented 2 papers on osteoporosis, Singapore: 12-22 September 1991.
  44. IGF1 and the Ovary, King George V Hospital, gynaecological endocrine course: 23 October 1991.
  45. Management of the symptomatic menopausal woman with breast cancer. Prince of Wales Hospital, 25 October 1991.
  46. The PCO syndrome, Family planning association seminar, Sydney, 27 October 1991.
  47. The PCO syndrome, Family planning association seminar, Brisbane, 2 November 1991.
  48. How common is the PCO amongst women with clinical and biochemical androgen excess? Australian Society for Ultrasound in Medicine, Sydney: 8 November 1991.
  49. Hormone replacement therapy, Rural Doctors Network meeting, Bowral, 9-10 November 1991.
  50. RACOG Part 2 course, Sydney, 2 sessions on gynaecological endocrinology.
  51. The PCO syndrome, Garvan Institute of Medical Research: 28 November 1991.
  52. The Menopause, RACOG Diploma course, Sydney, 2 February 1992.
  53. The Menopause, RACGP course, Sydney, 14 February 1992.
  54. Dysfunctional uterine bleeding, Rural Doctors Network meeting, Coffs Harbour, 28-29 March 1992.
  55. Acne as an endocrine disorder, RHW scientific meeting, 4 April 1992.
  56. The effect of ageing on small human (cohort) follicles. Australian Menopause Society Congress, Melbourne, 7 April 1992. (Awarded prize for best presentation).
  57. Follicles from polycystic ovaries are not normal small follicles. Royal Australian College of Obstetricians and Gynaecologists scientific meeting, Melbourne, 9 April 1992.(Awarded prize for best presentation).
  58. Perils of amenorrhoea, Wollongong Hospital, 15 April 1992.
  59. The Menopause, Lismore Hospital, 1 May 1992.
  60. Chaired Teleconference on transdermal oestrogen therapy, Sebel Town House, Sydney, 17 June 1992.
  61. IGF1 and the ovary, St Thomas' Hospital, London, 3 July 1992.
  62. IGF1, insulin and the PCO syndrome, Charing Cross Hospital, London, 6 July 1992.
  63. The hormonal therapy of acne. British Congress (RCOG), Manchester, UK, 10 July 1992.
  64. Role of IGF1 in the regulation of the human ovary. Middlesex Hospital, UK, 16 July 1992.
  65. The Menopause, Private Hospitals Association, Darling Harbour, 24 July 1992.
  66. The Menopause & abnormal uterine bleeding. Rural Doctors Network meeting, West Wyalong, 1-2 August 1992.
  67. The role of HRT. Rural Doctors Network meeting, Port Macquarie, 7-8 August 1992.
  68. The Menopause. RACOG scientific meeting, Gold Coast Queensland, 22-23 August 1992.
  69. The Perils of amenorrhoea. RACOG scientific meeting, Gold Coast Queensland, 22-23 August 1992.
  70. The Polycystic ovary syndrome, RACOG, Victorian Branch, Scientific meeting, 28 August 1992.
  71. The Menopause, Rural Doctor's Network Meeting, Canberra, 17 October 1992.
  72. Hormones and skin. RACD (dermatologists), Melbourne, 23 October 1992.
  73. Gynaecological endocrinology, RACOG Part II course, Sydney, 25 November 1992.
  74. Growth Factors and PCO syndrome, Fertility Society of Australia Scientific meeting on PCOS, Adelaide, 1 December 1992.
  75. The Menopause, RACOG diploma course, 31 January 1993.
  76. Hormones after breast cancer, Illawarra Cancer Care Centre, Wollongong, 13 February 1993.
  77. Management of hirsutism. Rural Doctors Network Meeting, Coffs Harbour, 27-28 February 1993.
  78. Hormones after breast cancer. Rural Doctors Network Meeting, Coffs Harbour, 27-28 February 1993.
  79. Primary amenorrhoea, RHW Scientific meeting, Paddington, 6 March 1993.
  80. Short-term symptoms of the menopause, RHW postgraduate meeting, ANA Hotel, 13 April 1993.
  81. HRT after breast cancer, RHW postgraduate meeting, ANA Hotel, 14 April 1993.
  82. Polycystic ovary disease, Current Concepts Seminar, Australian Association of Clinical Biochemists, Park Royal Hotel, Parramatta, 16 April 1993.
  83. A case controlled study of continuous combined hormone replacement therapy after breast cancer (Invited speaker) International Menopause Society Meeting, Stockholm, 21-24 June 1993.
  84. Hormones after breast cancer, Johns Hopkins University, Baltimore, 28-30 June 1993. Presented to the Departments of Endocrinology, Geronotology and Gynaecology.
  85. The Menopause and the PCO syndrome, St George Hospital Postgraduate meeting, 4 August 1993.
  86. Is hormone replacement therapy the answer for women? A debate, NSW Cardiac Rehabilitation Association, Marriot Hotel, Sydney, 28 July 1993.
  87. "Reflections on Stockholm - update from the 7th International Congress on the Menopause", Ritz-Carlton Hotel, 25 August 1993.
  88. A case controlled study of continuous combined hormone replacement therapy after breast cancer. North American Menopause Society Meeting, San Diego, California, USA, 2-4 September 1993.
  89. HRT and the GP. University of Sydney, 11 September 1993.
  90. Hormones after breast cancer. "Aspects of Gynaecology" Joan Sutherland Performing Arts Centre, 18 September 1993.
  91. A case controlled study of continuous combined hormone replacement therapy after breast cancer (Invited speaker). 3rd World Congress on Ultrasound in Obstetrics and Gynaecology, Las Vegas, Nevada, USA, 24-28 October 1993.
  92. The role of progestogens in hormone replacement therapy. Asia-Oceania Congress on Obstetrics and Gynaecology, Manila, the Philippines, 15-19 November 1993.
  93. The PCO syndrome, RACOG, part 2 course, Westmead Hospital, 29 November, 1993.
  94. "Is it my Hormones, Doctor?" The Hunter Postgraduate Medical Institute, Newcastle, 5 February 1994.
  95. "The Menopause". RACGP annual scientific meeting, 6-11 February 1994.
  96. Hormones after breast cancer. Australian Menopause Society Scientific meeting, April 17-20 1994 (Chairman, organising committee).
  97. A case-controlled study of oestrogen-progestogen therapy after breast cancer. Lancet conference, "The Challenge of Breast Cancer", Brugge, Belgium, 21-22 April 1994.
  98. Hormone replacement therapy after breast cancer. International Breast Cancer Study Group meeting, Lugarno, Switzerland, 23-25 April 1994.
  99. HRT: modalities of therapy. Coppleston postgraduate course, Sydney University, Saturday 14 May 1994.
  100. Australia-New Zealand tour, sponsored by Wyeth, "Hormones and Breast Cancer", visited Adelaide, Gold Coast, Brisbane, Auckland, Wellington, Perth, Bunbury, Wollongong, Parramatta, Newcastle, Albury, Melbourne, Canberra. June 1994.
  101. A twin study of Polycystic Ovaries, John Hunter Hospital, Newcastle. 15 June 1994.
  102. Hormones and breast cancer. 2nd International Symposium on Hormonal Carcinogenesis, Stockholm, 5-9 July 1994.
  103. Problems with HRT & HRT and breast cancer. Rural Doctors, Mudgee, 23, 24 July 1994.
  104. A twin study of polycystic ovary syndrome. Royal Hospital for Women, 9 August 1994.
  105. Menopause, mastalgia, PCO syndrome. Taree Hospital, 13-14 August 1994
  106. HRT after breast cancer, Illawarra Cancer Care Centre, Wollongong, 29 August 1994.
  107. HRT after breast cancer, St George Hospital Cancer Unit, 6 September 1994.
  108. Polycystic ovary syndrome. Adelaide, 9 September 1994
  109. Surviving the Forties, Family Planning Talk, 13 September 1994.
  110. Discordant twins and PCO. Fertility Society of Australia, Brisbane, 8-11 October 1994.
  111. Hirsutism and its management. RACOG part II course, Westmead Hospital, 29 November 1994.
  112. Dysfunctional uterine bleeding. Women's health update for GPs, Liverpool Hospital, 11 February 1995.
  113. Polycystic ovary syndrome in adolescents. XIth World Congress on Paediatric and Adolescent Gynaecology, Singapore, 23-26 February 1995.
  114. Prevention of breast cancer. Australian Menopause Society Meeting, Hobart, 23 May 1995.
  115. Hormones and breast cancer. 18 March 1995, Newcastle.
  116. HRT after breast cancer. 22-23 April 1995, Armidale.
  117. Phytoestrogens and menopause. 11 May 1995, Australia-Pacific Nutritionists meeting, Brisbane.
  118. Preventing breast cancer. 23 May 1995, Australian Menopause Society, Hobart.
  119. Hormones and the breast. 13 June 1995, St Vincent’s Hospital, Sydney.
  120. HRT after breast cancer. 3 July 1995, Australia and New Zealand Breast Cancer Trials Group, Alice Springs.
  121. HRT and cardiovascular function. 9 August 1995, Cardiac Society, Canberra.
  122. The Menopause. 12 August 1995. School of Nursing, Sydney University.
  123. Hormones and breast cancer. Family Planning Association, 3 August 1995.
  124. Phytoestrogens. RACOG annual scientific meeting, Perth, 27-30 September 1995.
  125. Hormones and Breast Cancer, Bowral, 11-12 November 1995.
  126. HRT after breast cancer. ANA Hotel, 30 November 1995.
  127. Amenorrhoea. RACOG diploma course, Sydney 17 January 1996.
  128. HRT and breast cancer risk. Hormones and cancer symposium, 10-11 February 1996, Novotel Hotel, Brighton, Sydney.
  129. Hormones and Breast cancer. Geelong Hospital, Victoria, 14 February 1996.
  130. Breast Cancer symposium. RACGP annual scientific meeting, Sydney University, 14 February 1996.
  131. Hormones and Breast cancer. NSW college of Nursing (COSA nurses), 20 February 1996.
  132. Phytoestrogens. Cancer Unit, St George Hospital, 21 February 1996.
  133. Breast cancer and the Menopause. Liverpool Health Service, Update Course in Obstetrics and Gynaecology, 23 February 1996.
  134. Hormone replacement therapy to prevent cardiovascular disease: Which patient? Which regimen? 6th International Congress on Cardiovascular Pharmacology, 29 February 1996, Sydney.
  135. Bleeding problems with HRT. Royal Hospital for Women, GP day, 30 March 1996.
  136. Hormones and Breast Cancer. Royal Hospital for Women, GP day, 30 March 1996.
  137. Polycystic ovary syndrome. Nepean Hospital, 10 April 1996.
  138. Hormones and breast cancer. Sutherland Hospital, 24 April 1996.
  139. HRT. RACGP course, 7 May 1996.
  140. Osteoporosis. GP conference, Adventist Hospital, 9 May 1996.
  141. HRT after cancer. Family Planning Course, Ashfield, 16 June 1996.
  142. HRT and the risk of developing breast cancer. St George Osteoporosis Support Group, 16 July 1996.
  143. Phytoestrogens. Hunter Postgraduate Medical Institute, 17 July 1996.
  144. HRT after breast cancer. NSW Cancer Institute Public Forum on Breast Cancer. Westmead Hospital, 12 October 1996.
  145. Fertility after cancer treatment. Hormones and Cancer Symposium, Sir John Clancy Auditorium, 23 February 1997.
  146. Alternatives to HRT. "Leading Edge in the South", Rydges Hotel, 1 March 1997
  147. Recent advances in Menopause, Novotel, Brighton, 18 April 1997.
  148. Natural Therapies for Menopause. Obstetrics and Gynaecological Society of Singapore, 26 April 1997.
  149. Natural Therapies for Menopause. Malaysian Menopause Society, 27 April 1997.
  150. Natural Therapies for Menopause. Malaysian Obstetrics and Gynaecology Society, Penang, 28 April 1997.
  151. Natural Therapies for Menopause. Australian Natural and Complementary Medical conference, Sydney, May 17, 1997.
  152. Managing the Menopause, Hilton, Sydney, 31 May 1997.
  153. Phytoestrogens. Fremantle, 9 June 1997.
  154. Natural therapies for menopause. Canterbury GP seminar, 8 July 1997.
  155. Natural Therapies for menopause. The Australia, New Zealand Breast Cancer Study Group, 10 July 1997.
  156. HRT for the difficult patient. Advanced course in obstetrics and gynaecology, 12 July, Sydney.
  157. Cabergoline - a new treatment for hyperprolactinaemia. Sydney, 15 July 1997
  158. HRT and the Cardiovascular system - St George Hospital, 29 July 1997
  159. Phytoestrogens. Royal Hospital for Women, 30 July 1997
  160. Periods, Pills and Potions. Osteoporosis seminar, St George Hospital, 11 August 1997
  161. Phytoestrogens. Nepean Hospital, 13 August 1997
  162. Alternatives to HRT. Philippines Climacteric Society, 7 September 1997.
  163. Norethisterone. Philippines Climacteric Society, 7 September 1997.
  164. Phytoestrogens. Royal Prince Alfred Endocrine Department, 24 September 1997.
  165. HRT. Novotel Darling Harbour, 27 September 1997.
  166. Lifestyle factors and breast cancer. National Breast Cancer Centre, Perth, 27 October 1997.
  167. The Great Debate - "HRT causes breast cancer", Australasian Menopause Society, October 1997.
  168. Phytoestrogens - latest studies. Australasian Menopause Society, October 1997.
  169. Phytoestrogens. National Breast Cancer Centre, Perth, 29 October 1997.
  170. Cabergoline. Perth, October 1997.
  171. Natural therapies after menopause. Women health Conference, Gold Coast, 27 February 1998.
  172. HRT after breast cancer. Women health Conference, Gold Coast, 29 February 1998.
  173. Long-term HRT. Singapore Obstetric and Gynaecology Society, 14 March 1998.
  174. Who to select for long-term HRT. Taiwan Obstetric and Gynaecology Society, 15 March 1998.
  175. HRT. GP meeting, Randwick 29 March 1998
  176. Phytoestrogens. RHW, Randwick, GP day 4 April 1998.
  177. PCO. RHW, Randwick, GP day 5 April 1998.
  178. HRT - the risks and benefits. Rydges, Parramatta, 6 May 1998.
  179. Complementary treatments & Women’s Health. Family Planning meeting, 28 June 1998.
  180. Natural Therapy for menopause, Family Planning Group, 28 June 1998.
  181. Sexuality and the Menopause, Sydney, 1 July 1998.
  182. Complementary Therapies, Australian Medical Student Association Meeting, Sydney, 8 July 1998.
  183. What’s current in HRT. RACOG diplomates course. 29 July 1998
  184. Management of postmenopausal women. RACGP course, 1 August 1998
  185. Phytoestrogens. Princes of Wales Hospital Grand Rounds, 5 August 1998.
  186. Menopause after breast cancer. Westmead Hospital, 16 September 1998
  187. HRT after breast cancer. NSW Cancer Council Talk, Westmead, 24 October 1998.
  188. HRT and heart disease. Cardiac Rehabilitation Association. Bankstown Hospital, 30 October 1998
  189. HRT after breast cancer. Breast Cancer Management course for registrars. 29 November 1998
  190. Menopause after breast cancer. Nepean Hospital, 10 February 1999.
  191. Menopause after breast cancer. Liverpool Oncology Group, 24 February 1999.
  192. Phytoestrogens. Westmead Hospital, 10 March 1999
  193. Menopause after Breast Cancer. Cancer Council 19 March 1999.
  194. Phytoestrogens. RHW, 9 April 1999
  195. Tamoxifen & HRT after endometrial cancer. RHW Oncology 3 day conference, 1 May 1999.
  196. Hormones and Breast Cancer. Hilton Hotel, Sydney, 15 May 1999
  197. Herbs for prostate disease. RACGP annual meeting, Homebush 21 May 1999.
  198. Menopause. Sydney University, 14 July 1999.
  199. Modern management of menorrhagia. 24 July 1999, Coffs harbour.
  200. HRT. 24 July 1999, Coffs harbour.
  201. Androgen therapy for women. Sydney, 28 July 1999
  202. Androgen therapy for women. Terrigal, 30 July 1999
  203. HRT after breast cancer. St George Grand Rounds, 11 August 1999
  204. HRT or herbs for menopause. Westmead Hospital week, 18 August 1999
  205. Menopause for diabetic women. 4th International Diabetes Federation Western Pacific Region. 25 August 1999. Sydney
  206. HRT or herbs for menopause. Liverpool Hospital meeting, 10 September 1999
  207. Diet and herbals for prostate disease. Annual Meeting, Genito-urinary oncology group, Sheraton Airport Hotel, Sydney, 14 September 1999
  208. Menopause and alternative therapies. Macarthur Division of GPs, 22 September 1999
  209. Research and complementary therapies. Integrative Medicine Conference, Manly 8 October 1999.
  210. Menopause after breast cancer. 9th international meeting on the Menopause, Yokohama, Japan, October 1999. (Chaired symposium).
  211. Soy for menopause. 3rd International Meeting on Soy, Washington DC, 31 October - 4 November 1999.
  212. Hormones and breast cancer. Anti-Aging conference, Sydney, 27 November 1999.
  213. HRT and the urinary tract. Annual meeting of urological nurses, Sydney, 8 December 1999.
  214. The effects of soy protein on men and women with elevated lipids. 2nd International Conference on food factors, Kyoto, 12-17 December 1999.
  215. Menopause and HRT, Terrigal, 9 February 2000
  216. Ovulation. Annual GP meeting for the Sydney Menopause Centre, 19 February 2000.
  217. Update on breast cancer and hormones. Annual GP meeting for the Sydney Menopause Centre, 19 February 2000.
  218. Polycystic ovary syndrome. Brisbane, 4 March 2000
  219. Hormones and breast cancer. Brisbane, 4 March 2000
  220. Can we prevent breast cancer? Royal Hospital for Women, 10 March 2000
  221. Menopause and treatment options for women with diabetes. 11 March 2000
  222. Osteoporosis. Rydges Hotel, Cronulla, 11 April 2000
  223. Managing Menopause after Breast Cancer. Annual Scientific Meeting of the Medical Oncology Group, Sydney, 27 April 2000.
  224. PCOS - genetic or environmental? Fertility Society of Australia, Canberra, 30 April 2000.
  225. Alternatives to HRT. RANZCOG registrars meeting, St George Hospital, 12 May 2000.
  226. Managing menopause. Newcastle, 17 may 2000
  227. Menopause after breast cancer. Wollongong Oncology group, 14 June 2000.
  228. Ginger for nausea - a RCT. RHW 17 June 2000
  229. HRT and breast cancer risk. Novotel Hotel Brighton, 21 June 2000
  230. PCO syndrome. POW hospital, 28 June 2000
  231. PCOS syndrome; Herbal Therapies. Sutherland GPs, 29 June 2000
  232. The genetics of PCOS. XVIIth Asian and Oceanic Congress of Obstetrics and Gynaecology, July 9-14, 2000. (Session convenor)
  233. Alternatives to HRT for managing menopause. Coppleson postgraduate meeting, 5 August 2000.
  234. HRT. Sydney, 12 August 2000.
  235. HRT and breast cancer, 4 lectures in New Zealand, 28-31 August 2000
  236. Livial, a new form of HRT. 6 October 2000, Newcastle.
  237. Phytoestrogens. Australasian Association of Clinical Biochemists, 24 October 2000.
  238. “One woman’s patch is not another woman’s bread” (a debate on HRT versus soy for menopause). International Conference of Endocrine Nurses, 1 November 2001.
  239. What’s new in menopause” Canberra, 3 November 2000.
  240. Evidence based herbals. Gold Coast GP meeting, 23, 24 February 2001.
  241. Preventing breast cancer. Gold Coast GP meeting, 23, 24 February 2001.
  242. Herbals for menopause. RHW meeting 24 March 2001
  243. Problems in Reproductive Medicine, Concord Hospital May 2, 2001-11-07
  244. Livial. RHW 9 May 2001-11-07
  245. Scientific method in herbal research, Uni NSW, 15 June 2001-11-07
  246. Is Soy safe? Uni NSW 16 June 2001-11-07
  247. Risk and benefits of HRT. St George Hospital, 4 July 2001-11-07
  248. Osteoporosis and the gynaecologist. 7 August 2001-11-07
  249. Menopause after Breast Cancer. 11 August 2001, Westmead Hospital
  250. PCOS. 23 August 2001, Garvan Institute
  251. HRT and the eye. Centre for eye research, Uni NSW, 21 September 2001-11-07
  252. HRT after breast cancer. Australasian Menopause Society meeting, 26 October 2001
  253. The LIFT study, Darling Harbour, 25 March 2002-08-12
  254. Managing menopause. Women’s hospitals Australasia & Children’s Hospitals Australasia, 9 April 2002
  255. Natural therapies. Women’s hospitals Australasia & Children’s Hospitals Australasia, 9 April 2002
  256. Managing menopause after breast cancer. Coffs Harbour, 10 May 2002
  257. Prevention of breast cancer. Royal Adelaide Hospital, 22 May 2002
  258. Menopause after breast cancer. Royal Adelaide Hospital, 23 May 2002
  259. The new biology of oestrogen. Royal Adelaide Hospital, 24 May 2002
  260. Menopause cases. Wollongong, 3 June 2002
  261. Poisonous herbs. Uni NSW, 22 June 2002
  262. Menopause cases. Campbelltown, 26 June 2002
  263. Menopause after breast cancer. Port Macquarie, 26 July 2002
  264. Livial. Gosford, 14 August 2002.
  265. Menopause Armidale, 21 September 2002.
  266. Herbals for Menopause, Melbourne, 26 October 2002.
  267. Menopause after breast cancer. Annual Hormone Update day, 15 February, 2003
  268. HRT and Herbals, Nowra Medical Association, 9 March 2003
  269. Cases in Reproductive Medicine, Nowra Medical Association, 9 March 2003
  270. RANZCOG meeting Cairns, 12 July. Polycystic Ovary Syndrome
  271. WHI, 1 year on. 24 July 2003.
  272. Where to after Pan? 20 September 2003.
  273. The media and HRT – the impact of the Women’s Health Initiative study. Annual meeting of the Australasian Medical Writers Association, 7 November 2003.
  274. Alternative therapies and menopause. Australasian Menopause Society, 13 November 2003.
  275. Where to after Pan? Australasian Pharmaceutical Science Association, Annual Conference 3 December 2003, Sydney.
  276. Polycystic ovary syndrome. RHW Annual hormone update day, 7 February 2004.
  277. The need for tissue-specific agents. International Gynaecological Endocrine Society, Florence, Italy, 27 February 2004.
  278. Managing menopause naturally. New Zealand branch of the RANZCOG, 14 March 2004.
  279. HRT in 2004. New Zealand branch of the RANZCOG, 14 March 2004.
  280. Osteoporosis and the gynaecologist. New Zealand branch of the RANZCOG, 14 March 2004.
  281. HRT after WHI. Adelaide, 2 July 2004-11-24
  282. Consensus meeting on HRT, RANZCOG 6-7 August 2004
  283. The Pill for women under 16 years of age. RHW 6 November 2004-11-24
  284. Menopause after breast cancer. Leura International Breast Cancer meeting. 12 November 2004-11-24
  285. Menstrual problems for women with PCOS. PCOS meeting, Melbourne 13 November 2004.
  286. Menopause after breast cancer. RHW meeting 19 November 2004.
  287. PCOS. Diabetes Australia 20 November 2004.
  288. Watson Memorial lecture, St George Hospital, 26 November 2004.
  289. The Health Benefits of soy - a clinician's viewpoint, Sydney Uni Department of Nutrition, 18 April 2005.
  290. Complimentary medicines and women's health. Department of Pharmacy, Sydney University, 6 May 2005.
  291. Managing menopause after breast cancer. Prince of Wales Hospital, 1 June 2005.
  292. PCOS and diabetes. Diabetes Australia, Canberra, 25 June 2005.
  293. The role of testosterone in the management of menopausal symptoms. GP Meeting, Brisbane.
  294. Managing menopause after breast cancer. Kconfab, Queensland, 31 August 2005.
  295. A randomised controlled trial of Remifemin. Australasian Menopause Society, 24 September 2005.
  296. Menopause after breast cancer. 10 November 2005.
  297. PCOS. Diabetes Australia, 19 November 2005.
  298. Update on Menopause, Hormone Update day, UNSW, 18 February 2006
  299. Surviving the 40s and 50s, POSSA meeting, Sydney, 30 September 2006.
  300. Managing menstrual problems, POSSA meeting, Sydney, 30 September 2006.
  301. Medical management of fibroids, Annual hormone update day, 17 February 2007.
  302. GP management of PCOS. Diabetes, obesity and heart summit; UNSW, 11 August 2007.
  303. “I don’t want to take hormones doctor.” 15 September 2007 Australasian Menopause Society, Adelaide
  304. Menopause after breast cancer. Albury, NSW,19 October 2007
  305. Non-hormonal options for menopause. GP Meeting, Clancy auditorium, UNSW, 16 Feb 2008
  306. Non-hormonal options for menopause, Melbourne, 15 March 2008.
  307. The Ageing woman, RHW, GP Update day, 5 April 2008
  308. A multicultural study of the menopause experience of women living in Sydney. International Menopause Society meeting, Madrid, May 2008.
  309. Menopause. St George GP group 25 June 2008
  310. Vaniqa – a new treatment for hirsutism. Melbourne 25 September 2008.
  311. Menopause after breast cancer. Canberra, 10 November 2008.
  312. HRT. Talk for RANZCOG Fellows, 11 November 2009
  313. LIBERATE trial, Sydney, 26 November 2008.
  314. PCOS. UNSW GP Meeting, 21 February 2009.
  315. Menopause, HRT and the endometrium. Registrars meeting, RHW, 27 February 2009.
  316. Is it safe to take HRT? 31 July 2009
  317. Therapeutic choices for menopausal symptoms. National Prescribing Service In service talk. 14 August 2009.
  318. Hormones and the breast. Sydney Square Breast Service in service talk, 27 August 2009.
  319. Therapeutic choices for menopausal symptoms. National Prescribing Service In service talk. 2 November 2009.
  320. Menopause after breast cancer. RNS Hospital Breast Cancer Group. 11 November 2009.
  321. Non-HRT options for menopause symptoms. Hormone Update Day, Clancy Auditorium UNSW, 20 February 2010.
  322. Menopause. Sutherland GPs. 17 March 2010.
  323. Treatment options for the menopausal woman who is still flushing at age 60. Prince of Wales Grand Rounds 23 June 2010
  324. HRT in postmenopausal women and in women with premature ovarian failure. Garvan Institute, 5 August 2010.
  325. Menopause. Rural Doctor’s Network, Moree; 16 September 2010
  326. Why does oestrogen only HRT not increase breast cancer risk: the role of stem cells. Friday oncology group, Prince of Wales; 24 September 2010.
  327. Breast cancer, stem cells and sex-hormones. June 2011, Roma
  328. Why does oestrogen-only hormone therapy have such a small impact on breast cancer risk? A hypothesis. June 2011, Roma
  329. Low libido and Women – Management Options and Testosterone Treatment. February 2012, Sydney
  330. Preventing breast cancer. Brisbane July 2012
  331. Low libido and Women – Management Options and Testosterone Treatment. Brisbane July 2012
  332. GP management of PCOS. July 2012
  333. Stem cells, hormones and breast cancer. Grand rounds RHW, August 2012
  334. Menopause - Ten years on from the WHI. RANZCOG annual meeting September 2012
  335. Using HRT. Androgen Insensitive Group September 2012
  336. Menopause - Ten years on from the WHI. Nowra, October 2012
  337. PCOS. Nowra, October 2012
  338. Sydney Bio-identical Hormones for Menopausal Symptoms. 16 Feb 2013 HealthEd, Sydney
  339. Evidence Based Herbs and Nutrients for Premenstrual Syndrome. 16 Feb 2013 HealthEd, Sydney
  340. Testosterone and Bio-identical Hormones for Menopausal Symptoms. 27.7.2013 HealthEd Brisbane
  341. Evidence Based Herbs and Nutrients for Premenstrual Syndrome. 27.7.2013 HealthEd Brisbane
  342. Evidence-based herbs and nutrients for PMS. RANZCOG scientific meeting, Sydney, 10 September 2013.
  343. Managing the menopausal woman, Australia Doctor Meeting, Sydney University, 19 October 2013.
  344. Contemporary management of menopause. 22 February 2014, HealthEd Meeting, UNSW.
  345. Androgen excess disorders. 15 March 2014, UNSW.
  346. Not all progestins are the same. HealthEd Sydney February 2015
  347. Managing menopause. HealthEd Sydney 20 February 2016
  348. Body Identical HRT. HealthEd Sydney 18 February 2017
  349. Body Identical HRT. HealthEd Melbourne 4 March 2017
  350. Body Identical HRT. HealthEd Brisbane 22 July 2017
  351. Body Identical HRT. HealthEd Perth 19 August 2017

Main Areas of Research - Summary

The Polycystic Ovary Syndrome

  • Aetiology
  • Pathogenesis
  • Diagnosis
  • Prevalence
  • Inheritance
  • Infertility & recurrent abortion
  • Treatment

Anovulation

  • Weight-loss
  • Exercise-induced
  • Health risks
  • Ovulation induction
  • Diet & reproduction

Regulation of the Ovary

  • Paracrine control
  • Insulin-like growth factors
  • Other peptide growth factors
  • Standardisation of tests

Menopause

  • Hormone replacement
  • Osteoporosis
  • Progestogens
  • Education
  • Breast cancer (cancer stem cells)
  • Cancer and HRT
  • Diet and menopausal symptoms
  • Phytoestrogens
  • Environmental oestrogens

Nutrition

  • Functional foods
  • Over-the-counter products
  • Cancer treatment and prevention
  • Lipid lowering
  • Cardiovascular disease treatment and prevention
  • Menopause syndrome
  • Isoflavones
  • Lignans

Herbals

  • Menopause
  • PMT
  • Headache
  • Nausea
  • Black cohosh
  • Soya
  • Ginger
  • Chaste tree extract

Biofilms

  • Twin study
  • Recurrent Candida
  • Sampling technologies

Teaching

Undergraduate teaching

I regularly lecture the medical students and hold tutorials. I also teach students in my outpatient clinics at the Royal Hospital for Women and previously at St George Hospital. I regularly give lectures to undergraduates both on the UNSW campus and at the RHW.

Resident and Registrar teaching

I regularly teach the residents and registrars at RHW as well as around Sydney.

Higher Degree Students

NameDegreeYear beganStatus
S JananfarPhD1990passed
J DewMD1994passed
R ManochaPhD1998 (2009 completed)passed
Mandy HubbardMSc2002passed

Annual Hormone Update Day

Every February, I help organise the largest GP meeting in Australia (with HealthEd). Typically over 1,000 health professionals attend our one day meeting on women’s health.

Administration

I have been a senior academic at UNSW and a senior medical officer at RHW for over 25 years. As Director of the Sydney Menopause Centre and the Natural Therapies Unit, I work closely with the hospital’s senior executive. I have been on the gynaecology committee (which reviews gynaecology services at RHW) since 1998. I have attended a number of in-service, work safety course within the public hospital and UNSW systems as well as other managerial courses in the private sector (e.g. on dispute resolution and improving my managerial skills).

Media

I have also had considerable experience giving talks for women's groups, as well as for radio and television. I am often approached by the media for comments on issues concerning herbals, menopause and breast cancer. I have a close working relationship with the hospital and UNSW PR staff. I have been on the advisory board of “Prevention” magazine since 2009. I have made several video clips for UNSW-TV.

Personal Details

I was born 31 December 1956 and have been married to Barbara for 37 years and have four children and four grandchildren. I enjoy fishing and reading.

Appendix 1

WHRIA and BGRU Team charter

Preamble: this team charter contains our unit’s guidelines for how we should relate to each other.

We, members of the Barbara Gross Research Unit are committed to the following:

  1. We value truth, integrity and loyalty.
  2. We treat each other, our clients, our sponsors and our hospital colleagues with respect.
  3. We encourage a spirit of cooperation in our unit; helping each other and promoting a safe environment (i.e. an amicable, non judgemental atmosphere) for the free exchange of ideas. We do not condone behaviour such as shouting, talking over the top of another person or gossiping.
  4. Conflicts will be resolved within our unit, using our conflict resolution protocol.
  5. We are committed to performing our tasks to the best of our ability, aiming to produce the highest quality of work.

Conflict resolution protocol

Our unit’s preferred method of conflict resolution will be as follows:

24-hour rule: when at all possible, conflicts will be resolved within 24 hours. If a staff member is really annoyed and unable to participate in the resolution process in a calm and respectful manner, they may need to have some time out (one or two days) to cool down. The preferred path of conflict resolution is outlined below in three steps.

  1. The two staff members involved in the conflict will meet privately, one-on-one, and try and resolve the problem. If this fails, step two will be implemented.
  2. The two staff members in conflict will then involve the other members of their team in the discussions to try and resolve the problem. If this fails, then move onto step three.
  3. Bring the problem to the director (currently associate Professor John Eden) or manager (currently Dr Jinzhu Liu).